Associated Papers
NSD Family-Mediated H3K36 Methylation in Human Cancer: Mechanisms and Therapeutic Opportunities.
Park JE et al.
Biomedicines, 2025
Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.
Caeiro LD et al.
Genes & Development, 2024
Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.
Caeiro LD et al.
Biorxiv : the Preprint Server for Biology, 2023
Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.
Kim S et al.
Chemical Biology & Drug Design, 2023
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Xiu S et al.
European Journal of Medicinal Chemistry, 2023
The T1150A cancer mutant of the protein lysine dimethyltransferase NSD2 can introduce H3K36 trimethylation.
Khella MS et al.
The Journal of Biological Chemistry, 2023
NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q et al.
Cancer Medicine, 2023
The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications.
Li Y et al.
Protein & Cell, 2023
Structural and functional specificity of H3K36 methylation.
Lam UTF et al.
Epigenetics & Chromatin, 2022
Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K et al.
Nature Communications, 2021
Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W et al.
Nature, 2021
Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
Yuan G et al.
Nature, 2021
Select a paper to view details